Pharvaris (PHVS) CHRO details option and RSU equity holdings

Rhea-AI Filing Summary

Pharvaris N.V. executive Annick Deschoolmeester, Chief Human Resources Officer, has filed an initial ownership report showing her equity interests in the company. She directly holds 92,553 shares of common stock, which include restricted stock units that vest over several years under prior equity awards.

She also holds stock options over additional Pharvaris common shares, including 60,000 options at $28.00 per share expiring on March 3, 2036, 60,000 options at $16.05 expiring on April 12, 2035, 45,000 options at $22.31 expiring on April 11, 2034, and 70,000 options at $8.05 expiring on April 6, 2033. These options and RSUs vest gradually, with portions vesting on specific dates and the remainder in monthly installments or annual tranches.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Deschoolmeester Annick

Role Chief Human Resources Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct); Common Stock — 92,553 shares (Direct)

Footnotes (1)

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -7,708 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Deschoolmeester Annick

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON 02421

(City) (State) (Zip)

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	92,553(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	03/03/2036	Common Stock	60,000	$28	D
Stock Option (Right to Buy)	(3)	04/12/2035	Common Stock	60,000	$16.05	D
Stock Option (Right to Buy)	(4)	04/11/2034	Common Stock	45,000	$22.31	D
Stock Option (Right to Buy)	(5)	04/06/2033	Common Stock	70,000	$8.05	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -7,708 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter; -3,554 RSUs from an award granted April 1, 2022 of which 25% vested April 1, 2023 with the remainder vesting 25% on each annual anniversary.

2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Annick Deschoolmeester	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Pharvaris (PHVS) Form 3 filing by Annick Deschoolmeester show?

The Form 3 shows Annick Deschoolmeester’s initial ownership in Pharvaris, including 92,553 common shares and multiple stock option grants. It details exercise prices, expiration dates, and vesting schedules for her options and restricted stock units under the company’s equity plan.

How many Pharvaris (PHVS) common shares does Annick Deschoolmeester beneficially own?

Annick Deschoolmeester directly holds 92,553 Pharvaris common shares. This amount includes restricted stock units granted under the company’s equity plan that settle in common shares and vest over time according to specified schedules described in the footnotes to the ownership report.

What stock options does the Pharvaris (PHVS) CHRO hold according to the Form 3?

The CHRO holds options over 60,000 shares at $28.00, 60,000 at $16.05, 45,000 at $22.31, and 70,000 at $8.05. These options expire between April 6, 2033 and March 3, 2036 and vest in initial 25% tranches and monthly installments.

How do Annick Deschoolmeester’s restricted stock units in Pharvaris (PHVS) vest?

Her RSUs vest partly in 25% initial tranches on specific anniversary dates, with remaining portions vesting monthly or annually. For example, a 20,000 RSU grant vests 25% on March 3, 2027, with the balance vesting monthly thereafter as long as conditions are met.

Does the Pharvaris (PHVS) Form 3 indicate any recent share purchases or sales?

The Form 3 functions as an initial ownership statement and lists existing holdings rather than recent market trades. The entries are coded as holdings with unknown transaction codes, so it does not report open-market purchases or sales by Annick Deschoolmeester.

What is Annick Deschoolmeester’s role at Pharvaris (PHVS) in this Form 3 filing?

In the filing, Annick Deschoolmeester is identified as an officer of Pharvaris, serving as Chief Human Resources Officer. The disclosure aligns her reported stock, RSUs, and option positions with her executive role, providing transparency around her equity-based compensation.